Executive Summary
This report details the operationalization of 12,500 Ayushman Arogya Mandir (Ayush) centres through the National Ayush Mission (NAM), focusing on upgrading existing dispensaries and sub-health centres. It outlines the strategic co-location of Ayush facilities within the primary health system, the financial utilization of ₹1802.15 crore, and the implementation of conservation schemes for medicinal plants. Key milestones include the achievement of co-location targets by December 31, 2025, and the launch of the Ayush Quality Mark Programme on December 19, 2025.
Key Points / Main Content
Infrastructure and Operationalization
Target Achievement: 12,500 Ayush Health & Wellness Centres (Ayushman Arogya Mandir) have been approved, including 10,941 upgraded dispensaries and 1,559 Sub Health Centres.
Co-location Strategy: Ayush facilities are integrated into Primary Health Centres (6,302), Community Health Centres (3,191), and District Hospitals (475) to provide patients with a "single window" for different medical systems.
Shared Responsibilities: The Ministry of Health & Family Welfare (under NHM) handles training and engagement of personnel, while the Ministry of Ayush (under NAM) provides infrastructure, equipment, and medicines.
Financial Allocation
Funding Utilization: Out of ₹1872.71 crore allocated/released under NAM over the last two financial years, ₹1802.15 crore has been utilized by State and UT governments.
Medicinal Plant Conservation and Development
NMPB Initiatives: The National Medicinal Plants Board (NMPB) supports in-situ/ex-situ conservation, R&D, and livelihood linkages through local committees and Self Help Groups.
Supply Chain Support: Support is provided for quality planting materials, post-harvest management, marketing infrastructure, and testing/certification of raw materials to increase profitability for farmers.
Quality Control and Regulatory Framework
Statutory Compliance: Manufacturers must strictly adhere to the Drugs & Cosmetics Act, 1940, and Good Manufacturing Practices (GMP) under Schedule T of the Drugs Rules, 1945.
Standardization: The Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) develops mandatory pharmacopoeial standards for drug identity, purity, and strength.
Testing Infrastructure: There are currently 118 private and 34 State/UT Drug Testing Laboratories functional to monitor medicine quality.
Quality Certification Initiatives
CDSCO Oversight: A dedicated Ayush Vertical facilitates joint inspections and the issuance of WHO Certificates of Pharmaceutical Products (WHO-CoPP).
Certification Marks: The QCI provides "Ayush Standard" and "Ayush Premium" marks based on third-party evaluations.
New Quality Programme: The Ayush Quality Mark Programme was launched on December 19, 2025, to enhance global recognition and quality assurance.
Impact Analysis
Patients
Impact: Patients benefit from increased access to Ayush treatments alongside conventional medicine through a single-window co-location system.
Action Required: Utilize the integrated facilities at PHCs, CHCs, and District Hospitals for diverse medical choices.
Ayush Drug Manufacturers
Impact: Manufacturers are subject to mandatory adherence to pharmacopoeial standards and GMP, with regular sampling and potential legal action for "Not of Standard Quality" products.
Action Required: Ensure compliance with Schedule T of the Drugs Rules, 1945, and apply for quality certifications (Standard/Premium marks) to enhance marketability.
State and UT Governments
Impact: They are responsible for the functional operation of upgraded centres and the utilization of allocated NAM funds.
Action Required: Continue regular reporting on fund utilization and maintain the operational status of the 12,500 approved health centres.
Farmers and Self-Help Groups (SHGs)
Impact: They receive support for the cultivation of medicinal plants, including infrastructure for post-harvest management and value addition.
Action Required: Engage with NMPB schemes for training, quality planting materials, and certification of raw materials.
Key Entities Referenced
National Ayush Mission (NAM): The primary mission under which Ayush dispensaries are upgraded and co-located with existing health centers to provide integrated medical systems.
Ayushman Arogya Mandir (Ayush): The rebranded Ayush Health & Wellness Centres being operationalized through the upgrading of dispensaries and sub-health centers.
Drugs & Cosmetics Act, 1940: The central legislation providing the regulatory framework and quality control requirements for Ayurvedic medicines.
Ayush Oushadhi Gunvatta Evam Uttpadan Samvardhan Yojana (AOGUSY): A central sector scheme implemented to support Ayush pharmacies and drug testing laboratories in achieving higher quality standards.
Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H): An organization that develops pharmacopoeial standards and serves as the appellate drug testing laboratory for Ayurvedic drugs.
AYUSH
Upgrading Ayush dispensaries under NAM
प्रव तथ: 21 JUL 2026 4:12PM by PIB Delhi
Under National Ayush Mission (NAM), 12500 Ayush Health & Wellness Centre now known as Ayushman
Arogya Mandir (Ayush) have been approved for operationalization by upgrading 10941 Ayush
Dispensaries and 1559 Sub Health Centres and as reported by States/UTs, all are functional.
The total funds of Rs. 1872.71 Crore has been allocated/released and as reported by State/UT
Governments, Rs. 1802.15 Crore has been utilized under NAM during the last two financial years.
Government of India has adopted a strategy of Co-location of Ayush facilities at Primary Health Centres
(PHCs), Community Health Centres (CHCs) and District Hospitals (DHs), thus enabling the choice to the
patients for different systems of medicines under a single window. The engagement of Ayush doctors/
paramedics and their training is being supported by the Ministry of Health & Family Welfare under
National Health Mission (NHM), while the support for Ayush infrastructure, equipment/ furniture and
medicines is being provided by the Ministry of Ayush under National Ayush Mission (NAM), as shared
responsibilities. 6302 PHCs, 3191 CHCs and 475 DHs have been co-located across the country as per the
NHM-Medical Information System (MIS) database as on 31.12.2025.
National Medicinal Plants Board (NMPB), Ministry of Ayush, Government of India is implementing
Central Sector Scheme on “Conservation, Development and Sustainable Management of Medicinal
Plants” throughout the country to promote the cultivation of medicinal plants wherein following activities
are supported:
i. Information Education & Communication (IEC) activities like Training / Workshops /
Seminars/ Conferences etc.
ii. In-situ conservation / Ex-situ conservation.
iii. Livelihood linkages with Joint Forest Management Committees (JFMCs) / Panchayats / Van
Panchayats / Biodiversity Management Committees (BMCs) / Self Help Groups (SHGs).
iv. Research & Development.
v. Promotion, marketing and trade of medicinal plants produce.
vi. Forward and backward linkage in supply chain of medicinal plants (Integrated Component)
under which the following activities are supported:
Infrastructure for Quality Planting Material to raise the planting material of medicinal plants for
cultivation.
Information Education Communication (IEC) activities to aware the farmers.
Infrastructure for Post-Harvest Management and Marketing to increase the marketability of the
medicinal plants, adding value to the produce, increasing profitability and reducing losses.
Testing and Certification of raw material.
The following measures are being implemented to ensure quality control of Ayurvedic medicines:
1. The Drugs & Cosmetics Act, 1940 and Drugs Rules, 1945 have exclusive regulatory provisions for
Ayurvedic drugs. It is mandatory for the manufacturers to adhere to the prescribed requirements forlicensing of manufacturing units & medicines including proof of safety & effectiveness, compliance
with the Good Manufacturing Practices (GMP) as per Schedule T of the Drugs Rules, 1945 for
Ayurvedic drugs and to follow the quality standards of drugs as prescribed in the Ayurvedic
pharmacopoeia.
Drug Inspectors collect medicine samples regularly from manufacturing firms or sale shops within
their jurisdiction and send them to Drug Testing Laboratory under Drug Control department for
quality testing and if any sample is found to be ‘Not of Standard Quality’, appropriate action is
initiated such as preventing the sale of the products from the market and appropriate legal actions as
per Drugs and Cosmetics Act 1940 and Rules made thereunder.
2. The Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), a subordinate
organization under the Ministry of Ayush, develops pharmacopoeial standards and formulary
specifications for Ayurvedic drugs, which serve as the official compendia for determining their
identity, purity, and strength. Compliance with these standards is mandatory under the Drugs and
Cosmetics Act, 1940 and the Rules made thereunder. PCIM&H also functions as the Appellate Drug
Testing Laboratory for Ayurvedic drugs and conducts regular capacity-building programmes for
Drug Regulatory Authorities, Drug Analysts, and other stakeholders on standardization, quality
control, and testing methodologies to strengthen the quality assurance system for Ayurvedic drugs.
3. Drug Testing Laboratories are being recognized under Rule 160 A to J of the Drugs Rules, 1945 for
carrying out such tests of identity, purity, quality and strength of Ayurvedic, Siddha, Sowa-Rigpa
and Unani drugs. As on date, 118 private laboratories and 34 Drug Testing Laboratories of
State/UTs are functional.
4. Ministry of Ayush has implemented Central Sector Scheme Ayush Oushadhi Gunvatta Evam
Uttpadan Samvardhan Yojana (AOGUSY) to support Ayush Pharmacies and Drug Testing
Laboratories to achieve higher standards under one of its components.
5. Further, the Ministry of Ayush promotes the following quality certification initiatives for Ayush
products:
Ayush Vertical in CDSCO: Strengthens regulatory oversight through joint inspections with State/UT
licensing authorities and facilitates issuance of WHO Certificate of Pharmaceutical Product (WHO-CoPP)
for eligible Ayush drugs.
QCI Quality Certification Scheme: Provides Ayush Standard Mark and Ayush Premium Mark based on
third-party evaluation of compliance with domestic and international quality standards.
6. Further, the Ministry of Ayush launched the Ayush Quality Mark Programme on 19.12.2025 to
strengthen quality assurance and enhance the global recognition of Ayush
This information was given by Union Minister of State (I/C) for Ayush, Shri Prataprao Jadhav in a written
reply in Rajya Sabha today.
***
SR/SV/SG
(रलीज़ आईडी: 2287052) आगंतुक पटल : 1096
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही